Related references
Note: Only part of the references are listed.High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
Tom Decroo et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis
Federica Fregonese et al.
LANCET RESPIRATORY MEDICINE (2018)
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
D. B. Cohen et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2018)
Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study
Ndivhuho A. Makhado et al.
LANCET INFECTIOUS DISEASES (2018)
Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis
Hans L. Rieder et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2017)
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree et al.
LANCET INFECTIOUS DISEASES (2017)
Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels
Ina Jeong et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2015)
Share Paper
